NAPPA and TONACEA join forces ahead of CPIC 2026
A strategic partnership ahead of the China Pharmaceutical Innovation and Competitiveness Conference (CPIC) 2026, formalizing a joint commitment to cross-border execution between U.S. and Chinese biopharma.
NAPPA and TONACEA have officially joined forces in advance of CPIC 2026 (China Pharmaceutical Innovation and Competitiveness Conference), formalizing a strategic partnership to advance cross-border collaboration between U.S. and Chinese biopharma.
The partnership unites NAPPA’s Boston-based, execution-oriented platform with TONACEA’s depth of relationships across Chinese innovators, regulators, and investors — building shared infrastructure for partnership origination, due diligence, and post-deal execution.
What the partnership covers
- Joint programming at CPIC 2026, including invitation-only roundtables for licensors and licensees.
- Shared deal pipeline development across oncology, CNS, and rare disease assets.
- Co-developed market-access frameworks for products moving in either direction across the Pacific.
More details on the CPIC 2026 program will follow ahead of the event.